Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.

Clin Cancer Res · 2022 · PMC9311322 · PMID 34862248

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A trend toward an increase in Th1:Th2 ratio in Th cells was observed with both monotherapy (3 of 5 patients) and combination treatment (2 of 2 patients) but did not reach statistical significance ( Fig. 4A ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.